|
|
|
|
| LEADER |
01510nam a2200481 4500 |
| 001 |
PPN241356733 |
| 003 |
http://www.sudoc.fr/241356733 |
| 005 |
20191213020900.0 |
| 010 |
|
|
|a 978-1-138-79371-2
|b br.
|
| 010 |
|
|
|a 1-138-79371-X
|b br.
|
| 020 |
|
|
|a US
|b 2014033649
|
| 020 |
|
|
|a GB
|b B508727
|
| 035 |
|
|
|a ocn892043100
|
| 035 |
|
|
|a AU@000053687638
|
| 035 |
|
|
|a CHBIS010258089
|
| 035 |
|
|
|a CHVBK331745100
|
| 035 |
|
|
|a NLM101642342
|
| 035 |
|
|
|a UKMGB017019142
|
| 100 |
|
|
|a 20191209d2015 k y0engy0103 ba
|
| 101 |
0 |
|
|a eng
|
| 102 |
|
|
|a US
|
| 105 |
|
|
|a y a 001|y
|
| 106 |
|
|
|a r
|
| 181 |
|
|
|6 z01
|c txt
|2 rdacontent
|
| 181 |
|
1 |
|6 z01
|a i#
|b xxxe##
|
| 182 |
|
|
|6 z01
|c n
|2 rdamedia
|
| 182 |
|
1 |
|6 z01
|a n
|
| 200 |
0 |
|
|a Reimagining (bio)medicalization, pharmaceuticals and genetics
|e old critiques and new engagements
|f edited by Susan E. Bell & Anne E. Figert
|
| 210 |
|
|
|a New York
|c Routledge, Taylor & Francis Group
|d 2015
|
| 215 |
|
|
|a 1 vol. (XI-274 p.)
|d 23 cm
|
| 320 |
|
|
|a Bibliogr. en fin de chap. Index.
|
| 606 |
|
|
|3 PPN029722373
|a Technologie pharmaceutique
|2 rameau
|
| 606 |
|
|
|3 PPN027424162
|a Biopharmacie
|2 rameau
|
| 606 |
|
|
|3 PPN02756987X
|a Génie génétique
|2 rameau
|
| 702 |
|
1 |
|3 PPN24135420X
|a Bell
|b Susan E.
|4 340
|
| 702 |
|
1 |
|3 PPN24135515X
|a Figert
|b Anne E.
|4 340
|
| 801 |
|
3 |
|a FR
|b Abes
|c 20191209
|g AFNOR
|
| 801 |
|
0 |
|b DNLM/DLC
|g AACR2
|
| 801 |
|
1 |
|b DLC
|g AACR2
|
| 801 |
|
2 |
|b YDX
|g AACR2
|
| 930 |
|
|
|5 441092207:652486169
|b 441092207
|j g
|
| 979 |
|
|
|a SOC
|
| 998 |
|
|
|a 861772
|
Nantilus
